EQT agrees to acquire Qiagen in an all‑cash €46.50‑per‑share takeover
Swedish private‑equity firm EQT announced an all‑cash offer of €46.50 per share for Qiagen, valuing the company at roughly €9.6 billion. The board of Qiagen unanimously approved the transaction, which carries an 8.6% premium to the last closing price and a 40.3% premium to the pre‑rumor price. The deal is subject to shareholder approval, regulatory clearances and is expected to close in mid‑2027, after which Qiagen will be delisted from the Frankfurt and NYSE exchanges.


